REPL
Time to buy REPL?$8.86
+$4.18 (89.32%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
REPL ran from the April 13, 2026 washout low of $1.50 to about $10.32 premarket on May 29 after the company said it plans to resubmit the RP1 melanoma BLA following productive talks with the Food and Drug Administration.
A failure to hold $8.00 could see a retrace toward $6.50 to $5.25. Any delay in the resubmission process, another negative regulatory read, or fresh concern about cash burn into early 2027 would accelerate the downside.
If REPL holds the $8.00 to $8.50 zone and volume stays heavy, a squeeze back toward $10.50 to $13.24 is on the table. Resistance at $10.00 is the first hurdle, and the roughly 30.2% short float can add fuel if buyers keep pressure on.
Analyst Ratings
Replimune Group Inc. Earnings
We don't currently have information about Replimune Group Inc.'s earnings.